Tél. : 0650740869

Technology

DIVINCELL has developed a unique and patented peptide-based nanoparticle platform DIV’INTM able to deliver into the pathologic cell the appropriate therapeutics to fight or prevent diseases.

 

Concept

The DIV’INTM Nanocage technology is a versatile nanoparticulate system, enabling the protection, packaging and tissue or cell specificity of biomacromolecules. It is based on more than 20 years of experience in the field of nanotechnology and targeted delivery of macromolecules.

DIVINCELL have designed and selected amphipathic peptides able to form stable self-assembled nanoparticles with a wide range of macromolecules.

Our breakthrough technology combines highly versatile delivery capabilities of amphipathic peptides with innovative targeting and tissue release approaches to improve drug delivery to organs of interest without altering their physiological balance.

Technology Properties

NANOCAGE DIV'INTM are:

  • Compatible with a wide range of therapeutic molecules (proteins, peptides, small molecules, nucleic acids…)

  • Modulable to offer targeting entities for specific delivery to tissues and organs
  • Applicable from hard to transfect sensitive cells to in vivo systemic or topical administrations

  • Lacking  of toxicity and of associate immune response.

 

DIVINCELL technology allows a wide range of molecule to reach their targets in the depths of previously inaccessible tissues and cellular compartments. We are currently exploring the potential  and versatility of our nanocage platform for multiple research and therapeutic applications.

 

 

 

Please contact us for more information about our technology and its applications.

 

Publications

  • Ding W. et al, (2018) EBioMedicine 38, 238–247

  • Divita G. et al, (2018) Cancer Res 2018;78(13 Suppl):

  • Konate K. et al, (2016) International Journal of Pharmaceutics 509, 71–84
  • Rydstrom A. et al, (2011). PLoS ONE. 6: e25924
  • Crombez L. et al, (2009). Nucleic Acids Res. 37, 4559-4569
  • Heitz F. et al, (2009), British Journal of Pharmacology 157,195–206
  • Morris, M.C.  et al, (2007). Nucleic Acids Research, 35, 49-59